Oral antidiabetics use among diabetic type 2 patients with chronic kidney disease. Do nephrologists take account of recommendations?

Journal of Diabetes and its Complications

Volumn 30, Issue 4, 2016, Pages 675-680

  Muller, Clotilde ^a,b,c   Dimitrov, Yves ^d   Imhoff, Olivier ^e   Richter, Sarah ^e   Ott, Julien ^d   Krummel, Thierry ^a   Bazin Kara, Dorothée ^a   Chantrel, Francois ^f   Hannedouche, Thierry ^a,b  

^a HÔPITAL CIVIL   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c Université de Strasbourg   (France)

^d Department of Nuclear Medicine   (France)

^e Nephrology and Transplantation Department   (France)

^f Mulhouse General Hospital   (France)

Author keywords

Chronic kidney disease; Diabetes mellitus; Drug safety; Kidney function estimation; Oral anti diabetic therapy

Indexed keywords

ACARBOSE; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; INSULIN; LIRAGLUTIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; REPAGLINIDE; SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN; ANTIDIABETIC AGENT;

AGED; ARTICLE; BODY SURFACE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONSULTATION; DIABETIC PATIENT; FEMALE; GENERAL PRACTITIONER; GLOMERULUS FILTRATION RATE; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; NEPHROLOGIST; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRESCRIPTION; PRIORITY JOURNAL; CHRONIC KIDNEY FAILURE; CLINICAL PRACTICE; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; CONTRAINDICATIONS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHY; DOSE CALCULATION; DRUG EFFECTS; DRUG MONITORING; ENDOCRINOLOGY; FRANCE; INAPPROPRIATE PRESCRIBING; KIDNEY; MANPOWER; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PROSPECTIVE STUDY; VERY ELDERLY;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG DOSAGE CALCULATIONS; DRUG MONITORING; ENDOCRINOLOGY; FEMALE; FRANCE; GENERAL PRACTITIONERS; GLOMERULAR FILTRATION RATE; HUMANS; HYPOGLYCEMIC AGENTS; INAPPROPRIATE PRESCRIBING; KIDNEY; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS'; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC;

EID: 84958581259     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2016.01.016     Document Type: Article

References (48)

1. Anonymous Health professionals CKD and drug dosing information for providers. Estimation of kidney function for prescription medication dosage in adults http://www.nkdep.nih.gov/professionals/drug-dosinginformation.htm Accessed 17 April 2011
2. R. Aronson, N. Orzech, C. Ye, R. Goldenberg, and V. Brown Specialist-led diabetes registries and predictors of poor glycemic control in type 2 diabetes: Insights into the functionally refractory patient from the LMC Diabetes Registry database Journal of Diabetes 8 1 2015 76 85
3. F. Bonnet, E. Gauthier, H. Gin, S. Hadjadj, J.-M. Halimi, and T. Hannedouche P. Zaoui Expert consensus on management of diabetic patients with impairment of renal function Diabetes & Metabolism 37 Suppl. 2 2011 S1 S25
4. J.C.N. Chan, R. Scott, J.C. Arjona Ferreira, D. Sheng, E. Gonzalez, and M.J. Davies D. Williams-Herman Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency Diabetes, Obesity & Metabolism 10 7 2008 545 555
5. S.-Y. Chen, Y.-C. Lee, V. Alas, M. Greene, and D. Brixner Outcomes associated with nonconcordance to national kidney foundation guideline recommendations for oral antidiabetic drug treatments in patients with concomitant type 2 diabetes and chronic kidney disease Endocrine Practice 20 3 2014 221 231
6. B. Detournay, D. Simon, P.-J. Guillausseau, D. Joly, B. Verges, and C. Attali O. Delaitre Chronic kidney disease in type 2 diabetes patients in France: Prevalence, influence of glycaemic control and implications for the pharmacological management of diabetes Diabetes & Metabolism 38 2 2012 102 112
7. N. Ekström, M. Miftaraj, A.-M. Svensson, K. Andersson Sundell, J. Cederholm, and B. Zethelius B. Eliasson Glucose-lowering treatment and clinical results in 163 121 patients with type 2 diabetes: An observational study from the Swedish national diabetes register Diabetes, Obesity & Metabolism 14 8 2012 717 726
8. M. Flamant, E. Vidal-Petiot, M. Metzger, J.-P. Haymann, E. Letavernier, and V. Delatour M. Froissart Performance of GFR estimating equations in African Europeans: Basis for a lower race-ethnicity factor than in African Americans American Journal of Kidney Diseases 62 1 2013 182 184
9. Guideline development group Clinical practice guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR) Nephrology, Dialysis, Transplantation 30 Suppl. 2 2015 ii1 ii142
10. C. Hasslacher, and Multinational Repaglinide Renal Study Group Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function Diabetes Care 26 3 2003 886 891
11. C.J. Hill, A.P. Maxwell, C.R. Cardwell, B.I. Freedman, M. Tonelli, and M. Emoto D.G. Fogarty Glycated hemoglobin and risk of death in diabetic patients treated with hemodialysis: A meta-analysis American Journal of Kidney Diseases 63 1 2014 84 94
12. A. Holstein, D. Nahrwold, S. Hinze, and E.H. Egberts Contra-indications to metformin therapy are largely disregarded Diabetic Medicine 16 8 1999 692 696
13. A. Holstein, and M. Stumvoll Contraindications can damage your health - Is metformin a case in point? Diabetologia 48 12 2005 2454 2459
14. S.C. Hung, U.K. Chang, J.S. Lin, K.L. Kuo, Y.H. Chen, and C.C. Hsu D.C. Tarng Metformin use and mortality in patients with advanced chronic kidney disease: National, retrospective, observational, cohort study Lancet Diabetes Endocrinol 3 8 2015 605 614
15. G.C. Jones, J.P. Macklin, and W.D. Alexander Contraindications to the use of metformin BMJ 326 7379 2003 4 5
16. F. Kajbaf, P. Arnouts, M. de Broe, and J.-D. Lalau Metformin therapy and kidney disease: A review of guidelines and proposals for metformin withdrawal around the world Pharmacoepidemiology and Drug Safety 22 10 2013 1027 1035
17. C.E. Koro, B.H. Lee, and S.J. Bowlin Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States Clinical Therapeutics 31 11 2009 2608 2617
18. J. Krepinsky, A.J. Ingram, and C.M. Clase Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with end-stage renal disease American Journal of Kidney Diseases 35 3 2000 500 505
19. J.-D. Lalau, P. Arnouts, A. Sharif, and M.E. De Broe Metformin and other antidiabetic agents in renal failure patients Kidney International 87 2 2015 308 322
20. A.S. Levey, J. Coresh, E. Balk, A.T. Kausz, A. Levin, and M.W. Steffes G. Eknoyan National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification Annals of Internal Medicine 2003 137 147
21. A.S. Levey, L.A. Stevens, C.H. Schmid, Y.L. Zhang, A.F. Castro, and H.I. Feldman J. Coresh A new equation to estimate glomerular filtration rate Annals of Internal Medicine 150 9 2009 604 612
22. P. Libby Metformin and vascular protection: A cardiologist's view Diabetes & Metabolism 29 4 Pt 2 2003 (6S117-20)
23. V. Lukashevich, A. Schweizer, Q. Shao, P.-H. Groop, and W. Kothny Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: A prospective 24-week randomized placebo-controlled trial Diabetes, Obesity & Metabolism 13 10 2011 947 954
24. R.H. Mak, and R.A. DeFronzo Glucose and insulin metabolism in uremia Nephron 61 4 1992 377 382
25. T.C. Marbury, J.L. Ruckle, V. Hatorp, M.P. Andersen, K.K. Nielsen, and W.C. Huang P. Strange Pharmacokinetics of repaglinide in subjects with renal impairment Clinical Pharmacology and Therapeutics 67 1 2000 7 15
26. G.R. Matzke, G.R. Aronoff, A.J. Atkinson, W.M. Bennett, B.S. Decker, and K.-U. Eckardt P. Murray Drug dosing consideration in patients with acute and chronic kidney disease - A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO) 2011 1122 1137
27. J. McCormack, K. Johns, and H. Tildesley Metformin's contraindications should be contraindicated CMAJ 173 5 2005 502 504
28. J.B. McGill, L. Sloan, J. Newman, S. Patel, C. Sauce, and M. Eynatten von H.J. Woerle Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: A 1-year, randomized, double-blind, placebo-controlled study Diabetes Care 36 2 2013 237 244
29. W.M. Michels, D.C. Grootendorst, M. Verduijn, E.G. Elliott, F.W. Dekker, and R.T. Krediet Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size Clinical Journal of the American Society of Nephrology 5 6 2010 1003 1009
30. National Kidney Disease Education Program Chronic kidney disease and drug dosing: Information for providers Available at: www.nkdep.nih.gov/professionals/drug-dosing-information.htm (Accessed Friday, June 11, 2010)
31. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification American journal of kidney diseases: The official journal of the National Kidney Foundation 2002 S1 S266
32. S.D. Navaneethan, P. Kandula, V. Jeevanantham, J.V. Nally, and S.E. Liebman Referral patterns of primary care physicians for chronic kidney disease in general population and geriatric patients Clinical Nephrology 73 4 2010 260 267
33. M. Nowicki, I. Rychlik, H. Haller, M.L. Warren, L. Suchower, I. Gause-Nilsson, and D1680C00007 Investigators Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment Diabetes, Obesity & Metabolism 13 6 2011 523 532
34. M. Nowicki, I. Rychlik, H. Haller, M. Warren, L. Suchower, and I. Gause-Nilsson K.M. Schützer Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: A randomised controlled 52-week efficacy and safety study International Journal of Clinical Practice 65 12 2011 1230 1239
35. H.J. Nye, and W.G. Herrington Metformin: The safest hypoglycaemic agent in chronic kidney disease? Nephron. Clinical Practice 118 4 2011 c380 c383
36. A. Penfornis, J.F. Blicklé, B. Fiquet, S. Quéré, and S. Dejager How are patients with type 2 diabetes and renal disease monitored and managed? Insights from the observational OREDIA study Vascular Health and Risk Management 10 2014 341 352
37. M.C. Petrie, J.G. Boyle, and G.A. McKay Use of metformin in chronic kidney disease should continue to be based on common sense in the absence of an evidence base Diabetic Medicine 32 7 2015 981 982
38. K. Rave, T. Heise, A. Pfützner, L. Heinemann, and P.T. Sawicki Impact of diabetic nephropathy on pharmacodynamic and pharmacokinetic properties of insulin in type 1 diabetic patients Diabetes Care 24 5 2001 886 890
39. B. Rosenkranz, V. Profozic, Z. Metelko, V. Mrzljak, C. Lange, and V. Malerczyk Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment Diabetologia 39 12 1996 1617 1624
40. R. Roussel, F. Travert, B. Pasquet, P.W.F. Wilson, S.C. Smith, and S. Goto P.G. Steg Metformin use and mortality among patients with diabetes and atherothrombosis Archives of Internal Medicine 170 21 2010 1892 1899
41. S. Schumacher, I. Abbasi, D. Weise, V. Hatorp, K. Sattler, and J. Sieber C. Hasslacher Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment European Journal of Clinical Pharmacology 57 2 2001 147 152
42. N.A. Smart, G. Dieberg, M. Ladhani, and T. Titus Early referral to specialist nephrology services for preventing the progression to end-stage kidney disease Cochrane Database of Systematic Reviews 6 2014 CD007333
43. A. Solini, G. Penno, E. Bonora, C. Fondelli, E. Orsi, and R. Trevisan G. Pugliese Age, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment in type 2 diabetes mellitus: Findings from the Renal Insufficiency and Cardiovascular Events Italian Multicenter Study Journal of American Geriatrics Society 61 8 2013 1253 1261
44. L.A. Stevens, T.D. Nolin, M.M. Richardson, H.I. Feldman, J.B. Lewis, and R. Rodby A.S. Levey Comparison of drug dosing recommendations based on measured GFR and kidney function estimating equations American Journal of Kidney Diseases 54 1 2009 33 42
45. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 352 9131 1998 854 865
46. W. Van Biesen, M. Wiedemann, and N. Lameire End-stage renal disease treatment: A European perspective Journal of the American Society of Nephrology 9 12 Suppl. 1998 S55 S62
47. M.A. Weir, T. Gomes, M. Mamdani, D.N. Juurlink, D.G. Hackam, and J.L. Mahon A.X. Garg Impaired renal function modifies the risk of severe hypoglycaemia among users of insulin but not glyburide: A population-based nested case-control study Nephrology, Dialysis, Transplantation 26 6 2011 1888 1894
48. H.J. Whittington, A.R. Hall, C.P. McLaughlin, D.J. Hausenloy, D.M. Yellon, and M.M. Mocanu Chronic metformin associated cardioprotection against infarction: Not just a glucose lowering phenomenon Cardiovascular Drugs and Therapy 27 1 2013 5 16